Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.7.0.1
Basis of Presentation and Significant Accounting Policies (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Mar. 07, 2017
Dec. 31, 2016
Noncontrolling Interest [Line Items]            
Accumulated deficit $ 63,413,508   $ 63,413,508     $ 57,004,655
Net loss 3,218,915 $ 2,925,221 6,408,853 $ 7,484,825    
Grant received for preclinical activities from CPRIT 411,250 411,250    
Non-controlling interest $ 90,166 $ 107,546 140,956 $ 282,428    
Pelican Therapeutics, Inc. [Member]            
Noncontrolling Interest [Line Items]            
Net loss     $ (72,252)      
Percentage of voting interests acquired in acquisition 80.00%   80.00%   80.00%  
Grant received for preclinical activities from CPRIT     $ 15,200,000      
Non-controlling interest $ 14,450   $ 14,450      
Heat Biologics I, Inc. [Member]            
Noncontrolling Interest [Line Items]            
Ownership interest in subsidiary 92.50%   92.50%     92.50%
Non-controlling interest $ 75,715   $ 126,506